Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Nevro Corp.

Nevro Corp. develops and offers solutions for chronic pain management through its HFX therapy technology, which includes FDA-approved devices and AI-based recommendations for pain relief.

msh id	COM:NEVRO
symbol	NVRO
name	Nevro Corp.
homepage url	https://www.nevro.com
country	US
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	1.22K
crunchbase url	-
linkedin url	-
founders	-

market cap	294.2M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.04
growth cost of revenue	0.13
growth depreciation and amortization	1.11
growth ebitda	0.57
growth ebitda ratio	0.59
growth eps	-33
growth eps diluted	-33
growth general and administrative expenses	-
growth gross profit	0.01
growth gross profit ratio	-0.04

COM:NEVRO

Nevro Corp.

Last Close

4.23

21/11 21:00

Market Cap

294.20M

Beta: -

Volume Today

422.78K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	524.48M
cost of revenue	524.48M
depreciation and amortization	11.54M
ebitda	-87.77M
ebitda ratio	-0.21
eps	-2.56
eps diluted	-2.56
operating expenses	377.83M
operating income	-99.31M
operating income ratio	-0.23

accounts receivables	-211K
capital expenditure	-8.59M
cash at beginning of period	120.37M
cash at end of period	104.22M
inventory	118.68M
working capital ttm	442.24M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-